European Archives - Page 943 of 983 - European Medical Journal

Paediatric Metabolic Conditions of the Liver

Paediatric metabolic disorders with the most clinical manifestations of deranged hepatic metabolism are discussed. The conditions which will be stressed…

Diagnosis and Management of Occult Hepatitis B Virus Infection: A Short Review

Occult hepatitis B virus infection (OBI) is a challenging clinical entity. It is defined as the presence of viral DNA in the liver or serum of subjects…

Occult HBV Infection Reactivation in Non-Hodgkin’s Lymphoma: An Update on Prevalence and Management

Occult hepatitis B virus infection (OBI) is characterised by the persistence of hepatitis B virus (HBV) genome in the liver…

Homozygosity For The C282Y Substitution In The HFE Gene: The Incomplete Penetrance And Variable Expressivity

The syndrome of hepatic cirrhosis diabetes and skin pigmentation (‘Bronze diabetes’) has been well documented, including its propensity to lead to…

How I Diagnose and Treat Acute (Fulminant) Liver Failure

Acute (fulminant) liver failure (ALF) is a rare but devastating clinical condition resulting in massive hepatocyte cell death.

EMJ Hepatology 3.1 2015

Future perspectives, new technology and treatments, innovation, best practice, and improving outcomes for patients are all features of this edition of…

EMJ

The Outdoors Meets Human Anatomy on New EMJ Covers

The novel creative graphics for our eJournal front pages have stemmed from a desire to make our covers more imaginative and interesting.

EMJ

Quick Imaging Unlocks Path to Valvular Heart Disease Treatment

ACCURACY of the physical diagnoses of heart conditions is boosted through the use of a handheld ultrasound device, with more successful diagnoses of…

EMJ

Key to Heart Attack Treatment May Come from Within

INTRACORONARY injection of a patient’s own bone marrow (BM) cells could emerge as the ultimate treatment for heart attacks.

EMJ

Basilea Announces That FDA’s Anti-Infective Drugs Advisory Committee Recommends Approval of Isavuconazole for the Treatment of Invasive Aspergillosis and Mucormycosis

Basel, Switzerland, January 22, 2015 – Basilea Pharmaceutica Ltd. (SIX: BSLN) today announced that the U.S. Food and Drug Administration’s (FDA)…